Table 3 Group demographics in sample II
|
Buprenorphine or Buprenorphine/ Naloxone (n= 18) |
Methadone (n= 18) | Group or time point comparison p-values | |
|---|---|---|---|
|
Age, years at T1 (M ± SD) | 30 ± 8 | 32 ± 8 | ns |
| Sex: females/males, % | 28/72% | 33/67% | ns |
|
Verbal IQ a
(M ± SD) | 101 ± 8 | 100 ± 11 | ns |
|
Education, years (M ± SD) | 10 ± 2 | 11 ± 1 | ns |
| Participants with early neurobehavioral problems % | 33% | 28% | ns |
| Examined in inpatient settings % | |||
| T2 | 6% | 6% | ns |
| T3 | 11% | 11% | ns |
| Participants with high frequency use of any substance of abuse % b | |||
| T2 | 44% | 39% | ns |
| T3 | 44% | 44% | ns |
| Participants with recent month extra doses of any opioid % c | |||
| T2 | 36% | 36% | ns |
| T3 | 36% | 43% | ns |
| Nicotine, participants using daily, % | |||
| T2 | 100% | 100% | ns |
| T3 | 100% | 100% | ns |
| Days in opioid substitution treatment at test (M ± SD) | |||
| T2 | 211 ± 19 | 196 ± 27 | ns |
| T3 | 411 ± 43 | 405 ± 29 | ns |
| Age of onset, any substance abuse (M ± SD) | 16 ± 4 | 15 ± 3 | ns |
|
Age of onset, opioid abuse (M ± SD) | 19 ± 5 | 19 ± 4 | ns |
| Participants with lifetime alcohol abuse | 72% | 83% | ns |
| Years of any substance abuse at T1 (M ± SD) | 15 ± 7 | 17 ± 7 | ns |
|
Years of alcohol abuse at T1 (M ± SD) | 3 ± 4 | 3 ± 3 | ns b |
| Years of opioid abuse at T1, years (M ± SD) | 10 ± 7 | 12 ± 7 | ns |